NASDAQ · Biotechnology

NeuroSense Therapeutics Ltd. (NRSN) Stock

$3.66 +2.23% NASDAQ: NRSN Healthcare

Valuation

MetricValue
Price$3.66
Market Cap$6.47M
P/E Ratio-0.54
P/B Ratio-3.13
P/S Ratio0.00
EPS (TTM)$-0.44
52-Week High$26.64
52-Week Low$3.58
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE723.04%
ROA-853.16%
ROCE587.30%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.11
Current Ratio0.33

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-6.0M$-14.0M$-12.0M$-10.0M$-11.0M
Net Profit$-4.0M$-12.0M$-10.0M$-10.0M$-11.0M
EPS$-4.60$-21.40$-16.60$-11.00$-8.80
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$11.0M$8.0M$3.0M$5.0M$1.0M
Total Liabilities$2.0M$2.0M$5.0M$2.0M$3.0M
Cash$11.0M$4.0M$3.0M$3.0M$0
Borrowings$0$0$0$0$0

Latest News

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" PR Newswire · Jul 6, 2026 NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint MT Newswires · Jun 29, 2026 NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS PR Newswire · Jun 29, 2026 NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease PR Newswire · Jun 25, 2026 EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots PR Newswire · Jun 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-8.0M$-8.0M$-10.0M$-8.0M
Investing Cash Flow$0$-4.0M$3.0M$0$0
Financing Cash Flow$1.0M$0$0$0$0
Net Cash Flow$10.0M$-8.0M$-1.0M$1.0M$-3.0M
Free Cash Flow$-2.0M$-8.0M$-8.0M$-10.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.15
EV / EBITDA-0.77
FCF Yield-54.44%
Quick Ratio0.31
Interest Coverage-1028.12
Return 1Y-63.69%
Return 3Y-47.14%
Return 5Y—

Ownership

Insiders Held32.31%
Institutions Held1.07%
Institutions Float Held1.59%
Institutional HolderSharesReport Date
Yorkville Advisors Global, LP78,0002026-03-31
UBS Group AG49,0962026-03-31
Independent Advisor Alliance50,0002026-03-31
Two Sigma Investments, LP44,4452026-03-31
Meitav Investment House Ltd.40,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CLGNCollPlant Biotechnologies Ltd. $3.51 -11.59% -0.37 $4.55M 0.00%
CVKDCadrenal Therapeutics, Inc. $0.91 -2.10% -0.19 $3.25M 0.00%
ENLVEnlivex Ltd. $0.25 -8.30% 0.03 $4.28M 0.00%
KLTOKlotho Neurosciences, Inc. $0.38 -7.10% -1.13 $20.08M 0.00%
NERVMinerva Neurosciences, Inc $3.18 -1.24% -0.12 $148.15M 0.00%

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is led by CEO Alon Ben-Noon, employs 17 people, headquartered in IL, publicly traded since 2021.

NeuroSense Therapeutics Ltd. (NRSN) stock trades at $3.66 with a market capitalization of $6.47M. The stock is valued at a price-to-earnings (P/E) ratio of -0.54, price-to-book of -3.13, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.58 and $26.64, and currently trades 86.3% below its 52-week high.

On profitability, NeuroSense Therapeutics Ltd. generates a return on equity (ROE) of 723.04% — well above the market average, a sign of a high-quality business, return on capital employed of 587.30%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides